Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 1st. Analysts expect Adamas Pharmaceuticals to post earnings of ($1.01) per share for the quarter.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.03 million. The firm’s revenue was down 90.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.78) earnings per share. On average, analysts expect Adamas Pharmaceuticals to post $-3.87 EPS for the current fiscal year and $-2.97 EPS for the next fiscal year.

Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) opened at 18.13 on Wednesday. The firm’s market cap is $408.18 million. The company’s 50 day moving average price is $20.80 and its 200-day moving average price is $17.83. Adamas Pharmaceuticals, Inc. has a 1-year low of $12.10 and a 1-year high of $24.18.

A number of equities analysts recently issued reports on the company. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Piper Jaffray Companies restated an “overweight” rating and issued a $30.00 target price on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. Zacks Investment Research cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, William Blair restated an “ourperform” rating on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Adamas Pharmaceuticals has a consensus rating of “Hold” and an average target price of $39.50.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.